Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mitsubishi Tanabe Pharma Launches Albumin Injection

This article was originally published in PharmAsia News

Executive Summary

Mitsubishi Tanabe Pharma announced May 19 that it had initiated sales of Medway Injections, recombinant human serum albumin preparations that are jointly developed with Bipha Corp, a MTP subsidiary. Currently, albumin preparations are derived from human plasma. The new products use pichia pastoris as a host and utilize gene recombination technology to reduce contamination by infectious materials in the production process and to enable mass production. Bipha is the manufacturer and Benesis Corp, another MTP subsidiary will co-promote the products. Genetically modified albumin products are approved in the U.S. and Europe as additives to vaccines. (Click here for more - Japanese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts